Optina has developed a hyper-spectral camera coupled with artificial intelligence-based technology that analyzes images of the retina to diagnose Alzheimer’s disease. The camera captures 92 images per second taken at different wavelengths revealing subtle phenotypic changes that may be related to various medical conditions.

Why we invested ?

It is estimated that approximately 50 million people worldwide are living with Alzheimer’s disease or dementia and that care costs more than $1 billion. These numbers could skyrocket to over 150 million people in the next 20 years if no breakthroughs are discovered.

Optina’s non-invasive early detection technology will be readily available to the population, take much less time than current solutions and cost a fraction of the price. Detection of the primary biomarkers of Alzheimer’s disease (amyloid) will be critical to accelerate clinical research to find a cure.